AMRI says it is well placed to win more NCATS contracts

AMRI gets 5-year NIH API manufacturing and process dev contract

By Gareth Macdonald

- Last updated on GMT

AMRI will work with NCATS technicians (source NIH)
AMRI will work with NCATS technicians (source NIH)

Related tags Switzerland Amri

AMRI has been hired by the NIH to provide synthesis and manufacturing services for APIs being developed by the National Center for Advancing Translational Sciences (NCATS) division of preclinical innovation.

The five year contract – financial terms of which were not provided – will see AMRI provide the NCATS Division of Pre-Clinical Innovation (DPI) with process and analytical development services and manufacture small molecule drug candidates for clinical trials.

An spokeswoman told us AMRI will be supporting progression of preclinical candidates to clinical stage, explaining "we will be supplying API for clinical trials​." She added the firm is also prepared to provide formulation services if required, but it is not covered under this contract.

She declined to share financial details of the specific project, but did suggest AMRI may be involved in other projects.

"NCATS’ total budget is $24.5m, but the budget is to be spread across three technical areas. There are eight awardees in total across the three technical areas. We anticipate that small molecule manufacturing will be the most prevalent technical area and that AMRI will have great success in winning work​."

The spokeswoman also told us that although AMRI does not anticipate hiring additional staff to work on the project, it is prepared to if the need arises.

Takeover speculation

News of the deal follows speculation​ AMRI had hired Credit Suisse Group AG to help it look for a buyer.

The firm told us “As a matter of corporate policy, we do not comment on rumors or speculation​.”

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more